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Aortic Aneurysm in Middle-aged Men
B. Lindblad,* G. Bo¨rner and A. Gottsa¨terDepartment of Vascular Diseases Malmo¨-Lund, Malmo¨ University Hospital, Lund University,
Malmo¨, SwedenObjectives. To investigate whether any variables in a health-screened population study were associated with later
development of large abdominal aortic aneurysms (AAA).
Setting. Malmo¨, Southern Sweden.
Material and methods. Within the Malmo¨ Preventive Study 22,444 men and 10,982 women were investigated between
1974 and 1991. The mean age at the health screening was 43.7 years.
Results. After a median follow-up of 21 years, 126 men and six women (p!0.001) had large AAA that were symptomatic
or evaluated for operation (5 cm diameter or more) or had autopsy-verified ruptured AAA. The male group (mean age 47
years) was, because of difference in age (p!0.001) also compared with an age-matched control group. The male patients with
AAA showed increased diastolic blood pressure (p!0.007) at the health screening. Smoking predicted the development of
AAA (p!0.0001). No difference in forced vital capacity or BMI was seen. Those who were physically inactive (e.g. not
walking or cycling to work) had an increased risk of developing AAA (p!0.001). Among the laboratory markers measured,
the erythrocyte sedimentation rate did not differ (7.1G5.9 vs. 6.4G5.7), but cholesterol (6.3G1.12 vs. 5.8G1.0) (p!
0.0001) and triglycerides (1.9G0.12 vs. 1.5G0.07) (p!0.001) were significantly elevated in these individuals who
subsequently developing AAA. The inflammatory proteins alfa-1-antitrypsin, ceruloplasmin, orosmucoid, fibrinogen, and
haptoglobulin were increased (p!0.001).
Conclusion. Male gender, smoking, physical inactivity and cholesterol are significant factors associated with the
development of AAA.Keywords: AAA; Associated risk factors; Atherosclerosis; Smoking; Hypercholesterolemia; Inflammatory markers.Introduction
Abdominal aortic aneurysm (AAA) is relatively
common in elderly men. Elastin and collagen degra-
dation, increased activity of matrix metalloprotei-
nases, inflammatory and immunologic activity, as
well as altered wall shear stress, may be causative
factors for the development of AAA.1 There are few
studies on factors associated with the development of
AAA during long-time follow-up in apparently
healthy individuals.2,3 Most studies have analysed
subpopulations or patients with confirmed AAA.4–10
Previous studies have shown age, male gender,
smoking, hypertension and high cholesterol levels to
be associated with the development of AAA.2–10
The evaluation of the incidence of AAA wasing author. Bengt Lindblad, Department of Vascular
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studies, but also on population screening studies in
which ultrasonography was used. In this study no
initial screening for AAAwas made and we included
only those from our population cohort who had
symptomatic AAA or AAA with a diameter larger
than 5 cm and were evaluated for treatment or
autopsy-proven ruptured AAA. The aim of this
study was to determine the risk factors associated
with development of large AAA in a population-based
cohort.Material and Methods
TheMalmo¨ Prevention Project11,12 is a health screening
and intervention programme carried out during a 17-
year period (1974–1991). A total of 22,444 men (mean
age 43.7G7 years) participated (participation rate
71%), of whom 126 were found to develop AAA. TheEur J Vasc Endovasc Surg 30, 346–352 (2005)
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Associated Factors for Development of AAA 347health screening programme also included a popu-
lation of 10,982 women, but in this group only six
individuals have been diagnosed with the develop-
ment of AAA (p!0.001).Health screening procedure
The health screening and examination procedures
have previously been described in detail.11,12 In brief;
heart rate and blood pressure (BP) were measured in
the right arm after 10 min’ rest. Bodymass index (BMI)
was calculated as kg/m2. Diabetes mellitus was
considered to be present, if there was a history of
treatment of diabetes or a fasting blood glucose level of
more than 6.7 mmol/l or equal. Smoking was defined
as current smoking at the time of participation in the
health screening programme. Forced vital lung
capacity (FVC), measured with a Spiroton apparatus
(Dra¨gerwerk AG, Lu¨beck, Germany), and activity
assessed from a questionnaire decided the measure
of physical fitness. The use of blood pressure-lowering
drugs, heart glycosides, nitro vasodilators and analge-
sic drugs was recorded.
Venous blood was collected after an overnight fast
in order to determine the erythrocyte sedimentation
rate (ESR), hematocrit and haemoglobin (Hb) levels,
total leukocyte count, platelet count, and serum total
cholesterol, triglycerides, total calcium, albumin,
creatinine, electrolytes, gamma glutamic acid transfer-
ase (GT), alanine amino transferase (ALAT), aspartate
amino transferase (ASAT), alkaline phosphatases
(ALP) and uric acid. The analyses were performed
by routine methods at the Clinical Chemistry Labora-
tory of Malmo¨ University Hospital. The fasting
capillary blood glucose level was determined in all
subjects.
Individuals who were health-screened and had
hypertension, hyperlipidemia, diabetes mellitus or
pathological glucose tolerance or high alcohol intake
were offered intervention and referred to outpatient
clinics. The Ethics Committee at Lund University
approved the study. All participants gave informed
consent.Patients and control groups
During the 28 years between the start of this health
screening programme and December 31, 2002, 126
men and six women of this cohort were documented to
have symptomatic or large (5–5.5 cm in diameter)
AAA. They either underwent operative reconstruction
(nZ98), were evaluated for aneurysm exclusion, but
treated conservatively (nZ19), or were found to haveautopsy-verified ruptured AAA (nZ15). This docu-
mentation was based on hospital register data,
SwedVasc quality control data and death certificates.
Only those who had objectively documented treat-
ment-requiring AAA were included in the analysed
group.
Plasma protein analyses were performed in a
subgroup of 6477 men of whom 63 developed AAA.
Details have been separately reported,10 but are
included to give as much information as possible on
the factors associated with the development of AAA.
Male patient baseline values for the different
variables at the time of health screening were
compared with the corresponding values for the case
control group established because of differences in
age. The closest birth date case not having AAA was
selected to the control group, but also to the entire
screened male population cohort (nZ22,444 [6477
regarding plasma protein analyses]).Statistics
Values are presented as meanGSD. The differences
between groups were assessed with the Mann–
Whitney U-test, or the chi-squared test as appropriate.
Because of the multiple comparisons, a post-hoc
adjustment using Bonferroni’s correction of p values
was performed, revealing that only p values below
0.01 should be considered as truly significant. The
relative risk of the development of AAAwas estimated
in terms of the odds ratio (OR) and the 95% confidence
interval (CI) for a one standard deviation increase (for
measurable variables) or in terms of the presence
versus absence of a given factor as determined by a
logistic regression analysis. The independent signifi-
cance of each variable was assessed by a multiple
logistic regression analysis after adjustment for other
significant risk factors. In this analysis p values less
than 0.05 were considered statistically significant.Results
Six women and 126 men developed AAA during the
observation period (p!0.0001). The median time
between the health screening and detection of AAA
was 21 years (range 6–30 years), and the median age at
the detection of AAAwas 68 years (range 49–81 years).
Male patients with AAA (nZ126) were further
analysed. At the health screening, this group was
significantly older (47 [37–60] years) than the entire
screened male population (nZ22,444, 43.7 [26–61]
years; p!0.0001). Therefore, we established an age-Eur J Vasc Endovasc Surg Vol 30, October 2005
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graphic data at health screening are seen in Table 1.
The male patients with AAA had higher diastolic
blood pressure (134/90 vs. 131/86 mmHg; p!0.007).
A significantly higher proportion of the patients
with AAAwere smokers at the health screening (81 vs.
51%; p!0.0001). Those who had smoked daily for
more than 10 years were even more frequent among
the patients who developed AAA (p!0.0001). The
subgroup of pipe smokers also seemed to have an
increased risk (p!0.08).
Reported alcohol consumption was not a risk factor
for the development of AAA. Neither were factors
such as being busy, easily stressed or suffering from
insomnia associated with later development of AAA.
The initial questionnaire from the health screening
showed that the case control group and entire male
population were more physical active (p!0.001) than
those who developed AAA. Forced vital capacity did,
however, not differ.
Laboratory data (Table 2) showed increased serum
total cholesterol (6.3G1.1 vs. 5.9G1.0 mmol/l; p!
0.0001), triglyceride (1.9G1.2 vs. 1.5G0.7 mmol/l; p!
0.0001), and plasma fibrinogen levels (3.95G0.65 vs.
3.50G0.80 mmol/l; p!0.001, Table 3) in subjects later
developing AAA.
We did not find any differences regarding the
recorded use of medication between the patients
with AAA and the control group or the background
health-screened population.
Furthermore, a logistic regression analysis was
performed to evaluate the variables that differed as
factors associated with later AAA. Smoking, physical
inactivity, and serum cholesterol remained as inde-
pendent associated factors (Table 4). Since fibrinogen
was only analysed in a subgroup of 63 patients with
AAA and 6477 of the background population, a
separate logistic regression analysis was performedTable 1. Baseline characteristics at the time of the health screening pr
case control series (age-adjusted)
AAA-group (nZ126)
Age (years) 47G6.1
Length (cm) 178G7
BMI (kg/m2) 25.4G3.2
Systolic BP (mmHg) 134G19
Diastolic BP (mmHg) 90G11**
COHb (%) 4.0G3.0
FVC (l/min) 4.2G0.9
FEV1.0 (l/s) 3.3G0.7
Smoking (%) 81***
Physical active (%) 20***
Results (but no statistical comparison) on the total screenedmale popula
01; ***p!0.001 for comparison between AAA-group and case controls.
FVC, forced vital capacity; FEV1.0, forced expiratory volume in 1 s.
Eur J Vasc Endovasc Surg Vol 30, October 2005in this group in which fibrinogen was not an
independent predictor (pZ0.062).
There were no differences concerning the health
screening variables between subjects operated on
because of ruptured, symptomatic or asymptomatic
AAA. Neither were there any significant differences
concerning associated factors in the patients with
AAA, with different time intervals between the health
screening and the development of AAA below or
above the median of 21 years after screening (data not
shown).
The absolute risk of developing a large AAA during
a 21-year follow-up of initially 47-year-old men was
0.56%, which was increased among the smokers to
0.9% (100 AAA among 11,403 smokers) compared
with 0.2% among the non-smokers (26 AAA
among11,041 non-smokers). In Fig. 1, we show the
absolute risk of different quartiles of serum total
cholesterol. In the highest quartile, we saw an absolute
risk of 1.2% compared with 0.1% in the lowest quartile
of serum total cholesterol values.Discussion
In recent years, we have learned much about the
pathology of AAA. Some of themore important factors
are elastolysis, impaired collagen production and
increased degradation, increased levels of matrix
proteinases, inflammatory reactions with increased
CRP levels, leukocyte and macrophage accumulation
in the aneurysmal wall, and increased immunological
activity.1
This study verifies earlier population-based studies
showing several factors associated with the develop-
ment of AAA such as male gender, smoking and high
cholesterol levels.2–10 A large number of case control
studies onpatientswithAAAhave focusedon these riskogramme of male individuals with detected AAA compared with a
Case-control group (nZ126) Screened males, (nZ22,244)
47G6.1 43.7G6.6
176G8 177G7
24.9G3.3 24.7G3.3
131G11 127G15
86G11 85G10
3.1G2.8 2.3G2.8
4.2G0.8 4.5G0.9
3.2G0.7 3.5G0.8
51 51
58 48
tion are also shown. Values presented as meanGSD. *p!0.05; **p!0.
BMI, body mass index; BP, blood pressure; COHb, carbon monoxide;
Table 2. Laboratory data at the time of the health screening programme of male individuals with detected AAA compared with a case
control series (age-adjusted)
AAA-group (nZ126) Case-control group (nZ126) Screened males (nZ22,244)
ESR (mm/h) 7.1G5.9 6.4G5.7 5.8G6.0
WBC (!109/l) 6.3G2.0 6.2G1.9 6.1G2.1
Hb (g/l) 146G9.7 147G9.3 148G9.7
Creatinine (mmol/l) 94G16 92G12 93G19
S-uric acid (mmol/l) 336G65* 318G67 324G64
S-total cholesterol (mmol/l) 6.3G1.1*** 5.8G1.0 5.6G1.1
S-triglycerides (mmol/l) 1.9G1.2*** 1.5G0.7 1.5G1.1
F-b-glucose (mmol/l) 4.9G0.8 4.8G0.7 5.0G1.0
S-GT (mkat/l) 0.73G0.50 0.90G1.48 0.69G0.96
Results, but without statistical comparison for the screenedmale population, also shown. Values presented as meanGSD. *p!0.05; **p!0.01;
***p!0.001; S, serum; P, plasma; F, fasting; b, blood; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; Hb, haemoglobin; GT,
glutamic acid transferase.
Fig. 1. The absolute risk of the development of AAA
depending on the level of cholesterol (divided in four
quartiles, with small differences due to the fact that many
had equal values).
Associated Factors for Development of AAA 349factors, and an association has been further verified
between AAA and age,4,5,7–9 male gender,4–10,13–19
smoking,2–10,13–17 total cholesterol3,5,8–10 and suggested
by several studies for hypertension,2,5,8–10,14,16–18,
arteriosclerosis,3,4,15 HDL-cholesterol4,7,8 and fibrino-
gen7,10 levels. In some case-control studies, an associ-
ation has been demonstrated between AAA and
triglycerides,10,20 cytokines,21–26 IL-6,22–25 TNF-a,24–26
acute phase reactants,27,28 oxidative stress,29Table 3. Inflammatory-related proteins in 6477 men (previously
reported10) of whom 63 later (median 19 years) developed AAA
AAA-patients,
(nZ63)
Male screening
group (nZ6414)
Fibrinogen (g/l) 3.95G0.65 3.50G0.80 p!0.001
Alfa1-antitrypsin
(g/l)
1.40G0.28 1.27G0.27 p!0.001
Ceruloplasmin
(g/l)
0.36G0.07 0.32G0.07 p!0.001
Orosmucoid (g/l) 0.91G0.23 0.82G0.20 p!0.001
Haptoglobin (g/l) 1.69G0.79 1.38G0.68 p!0.001homocysteine,30,31 cystatein-C,32 plasmin–antiplasmin
complexes,33,34 elastin peptides and its inhibition,35,36
MMP-2,37,38 endothelin-1,39 macrophage migration,40
PAF,41 connective tissue defects,42–46 and shear
stress.47
This study is based on the Malmo¨ Preventive
Study. Since we only noted six AAAs in women in
the follow-up until now, we focused our analysis on
the male population. Most studies do have selection
bias. The majority included in this health screening
analysis were men and the acceptable attendance
rate was 71%. Undetected aneurysms at the health
screening or during the follow-up cannot be ruled
out, because patients were not routinely imaged.
These factors need to be taken into account when
analysing our data. Furthermore, some individuals
in the screened population have moved to other
areas, which also may have influenced our results.
Another limitation with our study is the suboptimal
autopsy rates. In Malmo¨, a high autopsy rate
remained until 1990,48 and was acceptable until
2000, but it is currently as low as in most western
countries with an autopsy rate of 10–15%. However,
we consider that the fairly large cohort of screened
patients, followed for a median of over 20 years,
still makes our results valuable, and the majority of
clinically important aneurysms should have been
recognized in our population.Table 4. Logistic regression analysis of variables found to
significantly differ between the AAA group and the case control
group (Odds ratio for 1 SD or yes/no questions, 95% confidence
intervals)
Odds ratio 95% CI p
S-triglycerides 1.28 0.92–1.79 0.1453
Diastolic blood pressure 1.29 0.99–1.67 0.0692
S-cholesterol 1.45 1.05–1.99 0.0227
Physical inactivity 2.67 1.42–5.01 0.0022
Smoking 3.51 1.92–6.44 !0.0001
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genes exhibiting a pattern of chronic inflammation,
matrix degradation, arteriosclerosis and smooth
muscle cell depletion,49–54 but this knowledge is
currently based on a limited screening of less then
1% of the genome. A familial history regarding AAA
among relatives was not taken at the health screening
in our population cohorts. An association between
familial incidence and AAA has been strongly
documented.55,56
How predictive are the associated factors—male
gender, smoking, physical inactivity and hypercholes-
terolemia—that we found? The presence of male
gender, smoking or high cholesterol value increased
the risk of the development of AAA many times, but
the majority of male, smoking, inactive patients with
hypercholesterolemia, will not develop AAA. In the
future, maybe pharmacological treatment can prevent
aneurysm formation? Genetical studies have localised
some of the factors contributing to the development of
aneurysm.49–54 Studies using beta-blockers, statins,
anti-inflammatory drugs, or matrix proteinase-inhi-
bition have found some effects on aneurysm
growth.57–59
Screening for AAA is currently under debate.
Inactive, smoking men with hypercholesterolemia
are a subgroup likely to benefit from screening. In
the group having these factors, the absolute risk of
developing AAAwas 5–10 times higher than in active,
non-smoking, normocholesterolemic male patients.
We know that screening programmes for AAA are
cost-effective, but the mortality from AAA is only
moderately reduced.60,61
In conclusion, we have confirmed male gender,
smoking and hypercholesterolemia to be associated
with the development of AAA. The fact that physically
inactive patients were more prone to develop AAA
was not previously established. It is an interesting
finding, but only based on a questionnaire 21 years
before AAA was diagnosed and therefore it needs to
be further confirmed. So far, 126 documented AAAs
have been seen in males with 21-years of follow-up
after the initial health screening.Acknowledgements
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